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Polypharmacy and Symptoms of Pain in Women with Fibromyalgia
Anna Young, BS ‘14 (R.N.), Virginia Commonwealth University
Mentor: Victoria Menzies, PhD, RN, Virginia Commonwealth University

Fibromyalgia (FMS) is a syndrome characterized by chronic widespread
pain (CWP), which has no known etiology, and coincides with other
life-altering symptoms including fatigue, mood disturbances, nonrestorative sleep, and muscular stiffness. Despite the multiple
medication classes that are typically used for the treatment of FMS,
there are no known studies assessing the efficacy of polypharmacy on
symptoms of pain in this patient population. While analgesic
medications, including opioid or opioid-like medications, are
commonly prescribed, the use of these medications for FMS has not
been fully described, including the potential incidence of analgesic
overuse. The primary purpose of this secondary analysis was to examine
how many classes of pharmacologic agents were used in a sample of
N=122 women diagnosed with FMS, the relationships between baseline
pain levels and medication use, controlling for self-reported levels of
fatigue and depression. Data was collected from two separate studies:
(a) a cross-sectional study to examine the relationship among stress,
symptoms and immune markers in women (N=50) with FM, and (b) an
RCT to examine the effect of a 10-week guided imagery intervention on
stress, self-efficacy, symptoms and immunity in women (N=72) with
FM. In both studies participants were asked to provide lists of currently
prescribed medications for treatment of their FMS-related symptoms
and complaints. Study outcomes revealed that participants were
prescribed 6 different classes of medications. These included opioids
analgesics, non-opioid analgesics, antidepressants, anticonvulsants,
muscle relaxants, and benzodiazepines. Baseline pain severity
(p=0.0106) and pain interference (p=0.0002) were significantly
associated with opioid use as compared to those individuals who did
not report opioid use. Study findings are considered preliminary data
for development of a larger study to examine efficacy of polypharmacy,
with and without opioids, for this chronic pain patient population and
the related potential risk of adverse effects and substance abuse.

Introduction
The primary goal of this research project was to examine the
relationships between pain levels and medication use in women
diagnosed with fibromyalgia. The project is a secondary analysis of
previously collected data from two studies conducted by Victoria
Menzies, PhD, RN. The data utilized for this project was selfreported baseline pain level scores (Brief Pain Inventory [BPI],
Cleeland, 1989) and self-reported medication usage from a sample
(N=122) of women with FM. Through examination of this data, we
were able to answer the following proposed research questions: (1)
“How many different classes of analgesic agents were used for
individuals with FM?” and (2) “Do baseline pain scores differ in
those individuals prescribed opioid medications compared to those
who do not report opioid use?”

Conclusion

Results/Discussion

Abstract

Table 1. Drug Use by Broad Categories in a Sample of N=122
Women with FM
Categories
Opioids
Non-Opioid Analgesics
Antidepressants
Anticonvulsants
Muscle Relaxants
Benzodiazepines
Any Non-Opioid Pain Med Use

% (n)
30% (37)
50% (61)
58% (71)
31% (38)
41% (50)
24% (29)
87% (106)

Table 2. Scale Scores by Opioid Use
Scale

Total
(n=122)

Opioid Use No Opioid Use Yes
(n=85)
(n=37

p-value

BPI Severity

5.39 (2.01)

5.09 (1.97)

6.10 (1.95)

0.01061

BPI
Interference

5.69 (2.54)

5.12 (2.44)

6.97 (2.29)

0.00021

The BPI Scores Range from 0 (no pain) to 10 (worst pain)
(Mild Pain 1 – 4; Moderate Pain 5 – 6; Severe Pain 7 – 10)

Study findings demonstrated that those participants who were
taking opioid medications reported higher levels of baseline
pain scores than those who were not taking opioids. Baseline
pain severity (p=0.0106) and pain interference (p=0.0002) scores
were significantly associated with opioid use as compared to
those individuals who did not report opioid use.
Pharmacologic interventions are predicated on the current best
understanding of FMS as a centralized pain condition (Clauw,
2014). Central pain conditions are those in which persistent
pain occurs as result of abnormal alterations of central
ascending and descending pain pathways, the outcome of which
is augmented central nervous system pain processing. That is,
pain persists in the absence of anatomic anomalies and without
there being any proof of nociceptive input from the peripheral
nervous system (Üçeyler et al., 2013; Clauw & McCarberg,
2012). Just as there is lack of objective evidence for nociceptive
signaling from the peripheral nervous system, medications
commonly used to treat peripheral pain, such as opioids, may
be ineffective for symptom reduction in FMS.

Further examination of pain management strategies is warranted in
this patient population, especially where potentially negative effects
of polypharmacy are considered.
Researchers have suggested that hyporeactivity of the hypothalamuspituitary-adrenal (HPA) axis, increased inflammatory processes, and/
or dysfunction of neurotransmitters in the brain (dopamine,
serotonin, norepinephrine, glutamate, substance P) are likely
associated with this centralized pain state in FMS Therefore,
medication management appears to be most often approached
within the context of neurotransmitters and their role in analgesic
activity. For example, pain relieving effects of anticonvulsants have
been attributed to reduced release of several pain pathway
neurotransmitters, particularly glutamate and substance P, both of
which play a facilitory role in pain processing (Mease, Dundon, &
Sarzi-Puttini, 2011; Üçeyler et al., 2013). Other neurotransmitters,
considered to contribute to inhibition of pain processing, are
norepinephrine, serotonin and gamma-aminobutyric acid (GABA)
(Clauw, 2014; Clauw & McCarberg, 2012).
Therefore it is recommended that future longitudinal studies should
include an examination of those medications which effect
modulating and inhibitory neurotransmitters and examine them in
relation to pain and other symptoms of fibromyalgia.
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